Mikrotübül İnhibitörlerinin Etki Mekanizmaları ve Sınıflandırılması
Özet
Kanser tedavisinde kritik bir role sahip olan mikrotübül inhibitörleri, hücre bölünmesi ve sinyal iletimi gibi hayati süreçlerde görev alan mikrotübüllerin dinamik instabilitesini bozarak etki gösteren anti-mitotik ajanlardır. Bu inhibitörler, etki mekanizmalarına göre temelde iki ana gruba ayrılır: Yüksek konsantrasyonlarda mikrotübül polimerizasyonunu bloke eden "destabilizan ajanlar" ile polimerizasyonu uyararak tübüllerin ayrılmasını engelleyen "stabilizan ajanlar". Destabilizan gruptan vinka alkaloidleri, tübülin dimerlerine bağlanarak metafaz arrestine yol açarken; benzersiz bir halikondrin B analoğu olan eribulin mesilat, mikrotübül büyümesini durdurur ve cGAS-STING bağımlı doğal immün sinyal yolağını aktive eder. Stabilizan grupta yer alan taksanlardan paklitaksel ve dosetaxel, beta-tübuline bağlanıp depolimerizasyonu inhibe ederek hücreyi apopitozise sürükler; yeni nesil kabazitaxel ise lipofilik yapısıyla kan-beyin bariyerini daha iyi geçer. Benzer şekilde etki gösteren epothilonlar ve ixabepilon ise taksanlardan farklı olarak beta subünitten bağımsız moleküler mekanizmalar kullanır, daha yüksek suda çözünürlüğe sahiptir ve taksan dirençli hücrelerde etkinlik gösterebilir. Sonuç olarak bu ajanlar, mitozu durdurup apopitozu tetikleyerek tümör çoğalmasını engeller.
Microtubule inhibitors, which hold a critical place in cancer treatment, are anti-mitotic agents that function by disrupting the dynamic instability of microtubules involved in vital processes such as cell division and signal transduction. These inhibitors are classified into two main groups based on their mechanisms of action: "destabilizing agents," which block microtubule polymerization at high concentrations, and "stabilizing agents," which stimulate polymerization and prevent disassembly. Among the destabilizing agents, vinca alkaloids bind to tubulin dimers to induce metaphase arrest, whereas eribulin mesylate, a unique halichondrin B analog, suppresses microtubule growth and activates the cGAS-STING-dependent innate immune signaling pathway. Within the stabilizing group, the taxanes paclitaxel and docetaxel bind to beta-tubulin to inhibit depolymerization and drive cells toward apoptosis; the next-generation cabazitaxel features a lipophilic structure that allows better blood-brain barrier penetration. Similarly acting epothilones and ixabepilone utilize molecular mechanisms independent of the beta subunit, offer superior water solubility, and remain effective in taxane-resistant cells. Consequently, these agents successfully arrest mitosis and trigger apoptosis to suppress tumor proliferation.
Referanslar
Perez EA, Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance, Mol Cancer Ther (2009) 8 (8): 2086–2095.
Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy.Curr Med Chem Anticancer Agents 2005;5:65–71
Waterman-Storer CM, Salmon ED, Microtubule dynamics: Treadmilling comes around again, Dispatch, volume 7, İssue 6, Pr 369-372
Vicente JJ, Wordeman L. Mitosis, microtubule dynamics and the evolution of kinesins. Exp Cell Res. 2015 May 15;334(1):61-9
Mukhtar E, Adhami VM, Mukhtar H. Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther. 2014 Feb;13(2):275-84.
Fanale D, Bronte G, Passiglia F, Calò V, Castiglia M, Di Piazza F et al., Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option? Anal Cell Pathol (Amst). 2015;2015:690916
Moudi M, Go R, Yien CY, Nazre M. Vinca alkaloids. Int J Prev Med. 2013 Nov;4(11):1231-5. PMID: 24404355; PMCID: PMC3883245.
Rowinsky E. The Vinca Alkaloids. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003
Gregory RK,Smith IE, Vinorelbine –a clinical review, British Journal of Cancer (2000) 82(12), 1907–1913
Drummond DC, Noble CO, Guo Z, Hayes ME, Park JW, Ou CJ, et al. Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. J Pharmacol Exp Ther. 2009;328(1):321-30.
Fermaint CS, Takahashi-Ruiz L, Liang H, Moobery SL, Risinger AL. Eribulin Activates the cGAS-STING Pathway via the Cytoplasmic Accumulation of Mitochondrial DNA, Mol Pharmacol 100:309–318
Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Molecular cancer therapeutics. 2005;4:1086–1095.
Dybdal-Hargreaves NF, Risinger AL, Mooberry SL. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res. 2015 Jun 1;21(11):2445-52.
Ojima I, Lichtenthal B, Lee S, Wang C, Wang X. Taxane anticancer agents: a patent perspective. Expert Opin Ther Pat. 2016;26(1):1-20.
Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011 Sep 15;71(18):6019-29.
Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M. Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. Biomed Res Int. 2015;2015:413076.
Ganguly A., Yang H., Cabral F. Paclitaxel-dependent cell lines reveal a novel drug activity. Molecular Cancer Therapeutics. 2010;9(11):2914–2923. doi: 10.1158/1535-7163.mct-10-0552
Li, Y., Hussain, M., Sarkar, S.H. et al. Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells. BMC Cancer 5, 7 (2005).
Li Y, Li X, Hussain M, Sarkar FH. Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray. Neoplasia. 2004 Mar-Apr;6(2):158-67.
Avramis VI, Nandy P, Kwock R, Solorzano MM, Mukherjee SK, Danenberg P et al.. Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells. Anticancer Res. 1998 Jul-Aug;18(4A):2327-38.
Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol. 1994 Jul;5(6):495-505
Cucinotto I, Fiorillo L, Gualtieri S, Arbitrio M, Ciliberto D, Staropoli N et al, Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?, Journal of Drug Delivery, 2013, Article ID 905091, 10 pages, 2013.
Vrignaud P, Semiond D, Benning V, Beys E, Bouchard H, Gupta S. Preclinical profile of cabazitaxel. Drug Des Devel Ther. 2014;8:1851-1867
Pivot X, Koralewski P, Hidalgo J, Chan A, Goncalves A, Schwartsmann G, et al. A multicenter phase II study of XRP6258 administered as a 1-hour i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol (2008)
Buey RM, JF Dı́az , Andreu JM, O'Brate A., Giannakakou P., Nicolaou KC et al, Interaction of Epothilone Analogs with the Paclitaxel Binding Site: Relationship between Binding Affinity, Microtubule Stabilization, and Cytotoxicity, Chemistry & Biology, Volume 11, Issue 2, 2004, Pages 225-236
Fumoleau P, Coudert B, Isambert N, Ferrant E. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007 Jul;18 Suppl 5:v9-15.
Guo F, Nimmanapalli R, Paranawithana S, et al. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 2002; 99:3419–26.
Yamaguchi H, Chen J, Bhalla K, Wang HG. Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. J Biol Chem 2004; 279:39431–7.
